The solution: talk to patients.
The regulator tells farmers to limit antibiotic use.
The drug maker added biotechs Optimer and Trius to the fold, a bid to dominate in hard-to-treat infections.
inVentiv adds new comms exec; Julie Bowen teams up with Mylan for allergy emergencies; Royalty raises the bid on Elan; Pfizer nixes non-Hodgkin's lymphoma drug in trials.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.